Our overall goal in this research has been and continues to be to design and develop a genital herpes vaccine(s) that would be effective around the world. Although considerable human disease is caused by herpes simplex viruses, there is no approved vaccine for HSV-1 or HSV-2. We have designed a replication- defective HSV-2 mutant viral strain that is efficacious in two different animal species. In the previous grant period we conducted characterization of our genital herpes vaccine candidate, HSV-2 dl5-29, and this vaccine technology was licensed to Sanofi Pasteur and they are developing and producing it for clinical trials. This was a major step forward for the advancement of this vaccine concept. However, there is a high prevalence of genital herpes in developing countries, in particular Sub-Saharan Africa, and genital herpes is associated with a 3-fold increased risk of HIV infection. We have found that our HSV-2 dl5-29 vaccine candidate induces protection against South African viruses in a murine model, but the protection against the South African viruses is not as good as against US viruses. Furthermore, the South African viruses show increased disease and replication in the animals immunized with all of the vaccines. Therefore, we hypothesize that the South African viruses show antigenic diversity and pathogenetic diversity, which we will explore in this proposed research. Research proposed in this application is aimed at modifying and further improving this vaccine candidate to optimize protection against viruses from Sub-Saharan Africa where there is a co-epidemic of HSV-2 and HIV infection. In this application our specific aims are to: 1. Test the hypothesis that there is antigenic and pathogenetic diversity among HSV-2 strains from around the world and that specific viral genetic backgrounds will need to be used as vaccine strains for optimal efficacy in Sub-Saharan Africa by a) determining the optimal genetic background for a replication-defective HSV-2 strain for use as a vaccine to immunize against HSV-2 strains from Sub-Saharan Africa and b) determining the basis for the difference in the pathogenesis of infection by clinical strains from the US versus South Africa. 2. Test the hypothesis that genetic modifications in immune evasion genes can improve the dl5-29 herpes vaccine candidate by a) replacing the UL41-2 virion host shutoff gene with the homologous HSV-1 gene, UL41-1, containing mutations in the RNase domain and b) by introducing mutations in the US3 gene, whose product inhibits interferon and inflammatory cytokine responses. 3. Test the hypothesis that mucosal priming with an HSV-1 vector expressing HSV-2 glycoproteins B and/or D followed by boosting with HSV-2 dl5-29 will provide superior protection against HSV-2 genital challenge as compared with immunization with dl5-29 virus alone.
Genital herpes is a serious medical problem for several reasons, including the genital disease it causes, the risk of life-threatening infection in neonates and immunocompromised individuals, and the increased risk of HIV infection. However, no vaccine for herpes has been licensed. This research will continue to improve one of the leading genital herpes vaccines so it is optimally effective, and this improved vaccine could have a major impact on public health worldwide by preventing herpes and HIV infections.
|Colgrove, Robert; Diaz, Fernando; Newman, Ruchi et al. (2014) Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain. Virology 450-451:140-5|
|Knipe, David M; Corey, Lawrence; Cohen, Jeffrey I et al. (2014) Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines". Vaccine 32:1561-2|
|Reszka, Natalia J; Dudek, Timothy; Knipe, David M (2010) Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 28:2754-62|
|Hoshino, Yo; Pesnicak, Lesley; Dowdell, Kennichi C et al. (2009) Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 200:1088-95|
|Hoshino, Yo; Pesnicak, Lesley; Dowdell, Kennichi C et al. (2008) Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26:4034-40|
|Brockman, Mark A; Knipe, David M (2008) Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection. Vaccine 26 Suppl 8:I94-9|
|Dudek, Timothy; Mathews, Lydia C; Knipe, David M (2008) Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 372:165-75|
|van Lint, Allison L; Torres-Lopez, Ernesto; Knipe, David M (2007) Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology 368:227-31|
|Brockman, Mark A; Verschoor, Admar; Zhu, Jia et al. (2006) Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells. J Virol 80:7111-7|
|Dudek, Tim; Knipe, David M (2006) Replication-defective viruses as vaccines and vaccine vectors. Virology 344:230-9|
Showing the most recent 10 out of 11 publications